Acute cardiac care & resuscitationRandomised controlled trial

Prothrombin Complex Concentrate vs Frozen Plasma for Coagulopathic Bleeding in Cardiac Surgery

JAMAPublished

  • Randomised controlled trial
  • unblinded
  • non-inferiority
  • multicentre (12 hospitals, Canada and US)

Authors' conclusion

In this unblinded randomized clinical trial, PCC had superior hemostatic efficacy and safety advantages to frozen plasma among patients requiring coagulation factor replacement for bleeding during cardiac surgery.

Study context

Population
Adults undergoing cardiac surgery with bleeding related to coagulation factor deficiency after termination of cardiopulmonary bypass420 in primary analysis
Participants
538 adults
Comparison
4-factor prothrombin complex concentrate (PCC) vs frozen plasma
  • PCCn = 265
  • Frozen plasman = 263reference
Primary endpoint
Hemostatic response (effective if no hemostatic interventions from 60 min to 24 h after treatment initiation)
Follow-up
24 hours

Primary result

Hemostatic effectiveness

Difference

17.6%

95% CI 8.7%–26.4%

P < 0.001

Events by treatment group

PCC vs Frozen plasma
difference 17.6% (95% CI 8.7%–26.4%); P < 0.001

Non-inferiority margin 10 as printed, not drawn

As reported in the abstract

Secondary outcomes

OutcomePCCFrozen plasmadifference (95% CI)P value
Transfusions (RBC, platelets, noninvestigational frozen plasma units) · fewer with PCCmean 6.6 (95% CI 5.7–7.7) unitsmean 9.3 (95% CI 8.0–10.8) units2.7 (1.0–4.4)P = 0.002

Safety

OutcomePCCFrozen plasmaRR (95% CI)P value
Serious adverse events36.2%47.3%0.76 (0.61–0.96)P = 0.02
AKI10.3%18.8%0.55 (0.34–0.89)P = 0.02

Original publication

Prothrombin Complex Concentrate vs Frozen Plasma for Coagulopathic Bleeding in Cardiac Surgery. JAMA. Published 27 May 2025. doi:10.1001/jama.2025.3501

Summarised from the published abstract; every number is checked against it